JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

Search

Certara Inc

Закрыт

СекторЗдравоохранение

7.22 -2.04

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

7.19

Макс.

7.37

Ключевые показатели

By Trading Economics

Доход

3.5M

1.5M

Продажи

46K

105M

P/E

Средняя по отрасли

118.571

84.243

Рентабельность продаж

1.458

Сотрудники

1,487

EBITDA

-6.5M

23M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+60.03% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

26 февр. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-557M

1.3B

Предыдущая цена открытия

9.26

Предыдущая цена закрытия

7.22

Новостные настроения

By Acuity

50%

50%

139 / 352 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Very Strong Bearish Evidence

Certara Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

8 февр. 2026 г., 23:57 UTC

Обсуждения рынка

Uranium Outlook Heats Up on Rising Demand, Uncertain Supply -- Market Talk

8 февр. 2026 г., 23:47 UTC

Обсуждения рынка

Gold Rises Amid Growing U.S.-Iran Tensions -- Market Talk

8 февр. 2026 г., 23:43 UTC

Обсуждения рынка

Nikkei Likely to Rise Sharply After Takaichi's Election Win -- Market Talk

8 февр. 2026 г., 23:34 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

8 февр. 2026 г., 23:34 UTC

Обсуждения рынка

Landslide Election Victory of Japan's LDP Positive for Risk Assets -- Market Talk

8 февр. 2026 г., 23:26 UTC

Обсуждения рынка

Yen Skittish; Nikkei Jumps On LDP Landslide -- Market Talk

8 февр. 2026 г., 22:55 UTC

Отчет

DBS Group 4Q Net S$2.36B Vs. Net S$2.62B >D05.SG

8 февр. 2026 г., 22:55 UTC

Отчет

DBS Group 4Q Net Interest Income S$3.59B Vs. S$3.83B>D05.SG

8 февр. 2026 г., 22:55 UTC

Отчет

DBS Board Proposes 4Q Dividend of 66 Singapore Cents/share>D05.SG

8 февр. 2026 г., 22:55 UTC

Отчет

DBS Group: 2025 Total Dividend at S$3.06/share >D05.SG

8 февр. 2026 г., 22:55 UTC

Отчет

DBS Group 4Q Net Weighed by Higher Tax Expense, Absence of Non-Recurring Gains Recrorded Last Year >D05.SG

8 февр. 2026 г., 22:55 UTC

Отчет

DBS Group 4Q Total Income S$5.33B Vs. S$5.51B>D05.SG

8 февр. 2026 г., 21:43 UTC

Обсуждения рынка

FX Intervention Watch Resumes After Japan Election Result -- Market Talk

8 февр. 2026 г., 21:16 UTC

Обсуждения рынка

Right Of Australian Politics Reshaped as One Nation Surges -- Market Talk

8 февр. 2026 г., 21:15 UTC

Обсуждения рынка

Japan's Election Outcome to Revive Takaichi Trade -- Market Talk

7 февр. 2026 г., 09:20 UTC

Обсуждения рынка

Financial Services Roundup: Market Talk

7 февр. 2026 г., 09:20 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

7 февр. 2026 г., 05:15 UTC

Обсуждения рынка

Global Commodities Roundup: Market Talk

7 февр. 2026 г., 02:46 UTC

Приобретения, слияния, поглощения

Big Money, High Anxiety -- Barrons.com

6 февр. 2026 г., 21:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

6 февр. 2026 г., 21:50 UTC

Обсуждения рынка

Financial Services Roundup: Market Talk

6 февр. 2026 г., 21:40 UTC

Приобретения, слияния, поглощения

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

6 февр. 2026 г., 21:22 UTC

Обсуждения рынка

Mexico's Inflation Seen Accelerating in January -- Market Talk

6 февр. 2026 г., 21:17 UTC

Отчет

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6 февр. 2026 г., 21:15 UTC

Обсуждения рынка

Global Commodities Roundup: Market Talk

6 февр. 2026 г., 21:14 UTC

Приобретения, слияния, поглощения

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

6 февр. 2026 г., 21:13 UTC

Отчет

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

6 февр. 2026 г., 21:13 UTC

Отчет

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

6 февр. 2026 г., 21:04 UTC

Обсуждения рынка

Gold Closes Out Volatile Week on Higher Note -- Market Talk

6 февр. 2026 г., 20:34 UTC

Отчет

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

Сравнение c конкурентами

Изменение цены

Certara Inc Прогноз

Целевая цена

By TipRanks

60.03% рост

Прогноз на 12 месяцев

Средняя 11.57 USD  60.03%

Максимум 13 USD

Минимум 9 USD

Основано на мнении 9 аналитиков Wall Street, спрогнозировавших целевые цены для Certara Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

9 ratings

6

Покупка

3

Удержание

0

Продажа

Техническая оценка

By Trading Central

11.27 / 12.79Поддержка и Сопротивление

Краткосрочная

Very Strong Bearish Evidence

Среднесрочная

Very Strong Bullish Evidence

Долгосрочная

Strong Bullish Evidence

Настроения

By Acuity

139 / 352Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Средняя

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat